I’ve reviewed a lot of things that promised more than they delivered. A “handmade” pasta maker that jammed on ravioli number three. A noise-cancelling headphone that cancelled nothing but my patience. But the NAD+ and NMN category deserves its own shelf, because the marketing budget is doing more work than the evidence, and somebody should say that plainly before you spend money finding out.
Last updated: June 2026, and worth repeating up front: NAD+ and NMN are sold as longevity products, and the human evidence that either one slows aging is thin. NMN comes as an oral supplement and also gets compounded. NAD+ is mostly compounded and delivered by IV or injection. Neither has FDA approval as an anti-aging drug, full stop. Every claim below traces back to a primary source, which, in this category, is rarer than it should be.
Here’s the thing I want to review instead of the compound itself: the buying experience. Because after going through the studies and the sellers, I’m convinced the question “which one should I take” is the wrong question to lead with. The question that actually protects you is “who is selling this to me, and do they know anything about my medical history.” That’s the review. Let’s grade it properly.
The hype
Scroll past any NAD+ ad and you’ll see words like “cellular reversal,” “biological age,” and “clinically proven,” stacked up like a Vegas marquee. The pitch is that your NAD+ pool crashes with age (true, actually) and that topping it back up will make you feel twenty-five again (considerably less true, or at least, nobody has shown it).
The decline part checks out. A 2012 study that measured NAD+ in human tissue from newborns to age 77 found levels fell steadily with age in both sexes [P5]. That’s a real, measured, unglamorous fact. What the hype skips is the second half of the sentence: whether topping the tank back up does anything for a person is, per the field’s own foundational review, still unknown [P4]. That’s not my skepticism talking. That’s the literature.
The honest grade
If I’m grading this category like I’d grade any product, here’s my report card.
NAD+, the coenzyme itself: incomplete. It’s the real thing your cells actually use, a required cofactor for the sirtuins and PARPs involved in DNA repair [P4]. Real credentials. But when a 2026 PRISMA-guided systematic review went looking for controlled outcomes trials of IV or IM NAD+ for anti-aging or wellness, it found none [P6]. Zero. You can have the best resume in the world and still not get called back for an interview. That’s IV NAD+ right now.
NMN, the oral precursor: a C+ trying hard. It has actual trials behind it, which already puts it ahead of the infusion crowd. A 2021 randomized, placebo-controlled trial in Science gave 25 postmenopausal women with prediabetes 250 mg per day for ten weeks and found improved muscle insulin sensitivity [P1]. That’s a genuine result, but it’s one outcome in one specific, small group, not a verdict on aging generally. A separate 2021 trial in amateur runners found some submaximal aerobic improvements, but VO2max, the number that actually defines aerobic fitness, didn’t budge [P2]. Supporting evidence comes sideways, from a 2018 trial of nicotinamide riboside (NMN’s cousin) that was well tolerated and reliably raised NAD+ in healthy middle-aged and older adults [P3]. Reliable at raising a biomarker. Unproven at changing how you feel or how long you live.
The category’s evidence base overall: needs improvement. That same 2026 review summed it up cleanly: oral precursors reliably raise NAD-related biomarkers, but clinical outcomes across the category are mixed, and nobody has run the IV trials at all [P6]. When a review paper is more honest than half the sellers citing it, that tells you something.
None of this means the compounds are useless. It means nobody gets to call this settled science, and any seller who does is grading on a curve that doesn’t exist.
What actually earns trust
Here’s where the review gets more interesting than “the science is unclear,” because that part, frankly, was never going to surprise you. The part worth your attention is that safety in this category isn’t really a property of the molecule. It’s a property of the transaction.
A supervised route looks like this: a licensed clinician reviews your history before you get anything, a prescription gets written if it’s appropriate, and a licensed pharmacy actually prepares the product. An unsupervised route looks like: add to cart, receive vial, good luck. For something as under-studied as IV NAD+, with zero controlled outcomes trials to its name [P6], the presence of a human being with a medical license between you and the syringe is not a nicety. It’s the whole safety mechanism.
FormBlends earns the top spot here, and it earns it for a boring, unglamorous reason: it’s structured as a supervised telehealth and compounding provider, not a storefront. Its public materials state that every compounded medication requires a licensed physician consultation and a prescription, and that everything is prepared by licensed 503A compounding pharmacies following USP <797> and <800> standards. NAD+ shows up in its longevity compounds, described in studied language rather than miracle language, and NMN sits in the same category. What that buys you is simple: the same molecules a research-chemical site mails you in an unlabeled vial get routed, here, through a prescriber, a real pharmacy, and follow-up. HealthRX (healthrx.com) operates on the same clinician-first model and sits right alongside it as a same-tier option.
I’ll give you the caveat too, because a review that only tells you the good news isn’t a review, it’s an ad. What the supervised model buys you is oversight: the clinician, the prescription, the pharmacy, the accountability. It does not buy you FDA approval, and it does not buy you a guarantee that the compound works. Given that IV NAD+ has no controlled trials behind it [P6], that oversight is precisely the value on offer, no more, no less. Also worth flagging: FormBlends states on its own site that it’s still finalizing its product catalog and compliance requirements, so check current availability before you assume anything’s ready to go.
The compound and the route, ranked honestly
If the access question is settled, the compound question is genuinely secondary, and I mean that. NMN is the more sensible entry point for most people new to this: it’s oral, it reliably raises NAD+ markers in human studies [P6], and it has a small but real trial record behind it [P1][P2]. IV NAD+ carries the premium price tag and the premium mystique, and the weakest evidence of the two [P6]. If you’re going to dip a toe in at all, dip it with the lower-intensity, better-documented option, under supervision, rather than booking an infusion the data hasn’t caught up to yet.
The delivery method matters for risk too. A capsule is a lower-stakes proposition than something you’re drawing into a syringe yourself. Which is one more argument, not against injectables categorically, but for keeping a clinician and a pharmacy in that loop if an injectable route is on the table at all.
Where the emperor really has no clothes
Every reviewer eventually has to name names, so here they are: Pure Rawz, Core Peptides, Limitless Life, and Biotech Peptides, the names you’ll bump into if you go looking for NAD+ or NMN outside a clinical channel. I’m not calling them scams. I’m calling them structurally incapable of giving you what a safe first purchase requires. Here’s the checklist, and how they fail it, one by one.
“Research use only” or “not for human consumption” labeling. This is the single most important tell in the whole category. That phrase isn’t legal throat-clearing, it’s the actual legal basis the product is sold under. Sell a chemical for lab use and you’re in one regulatory lane. Market the same chemical for a person to inject or swallow and it becomes an unapproved new drug, which is exactly why the disclaimer exists in writing. If you’re about to put something in your body and the label says “research use only,” that’s not fine print, that’s a warning label doing its job.
No clinician, no prescription. If the entire transaction is a checkout button, there is no medical judgment anywhere in the process, and for a compound this unsettled, that absence is the whole risk.
Cure language. Given that IV NAD+’s human-benefit evidence is essentially nonexistent [P6] and NMN’s results are narrow and specific [P1][P2], any seller promising reversed aging is telling you something the data doesn’t support, and that’s worth remembering the next time they tell you something else too.
A seller-issued Certificate of Analysis waved around as independent proof. A COA the seller commissions and posts themselves is better than nothing, technically, but it’s their homework, graded by them. It’s not independent, it’s not FDA-equivalent, and it puts no clinician or pharmacy anywhere near your order. Mistaking it for proof is the most common beginner error I’d flag.
Price as the headline feature. When “cheapest on the market” is the pitch, that’s a seller competing on the one metric that tells you nothing about whether the product is real, pure, or safe.
Run any of the four names above against that checklist and they land in the same place: no clinician, no prescription, no pharmacy dispensing, purity you can’t independently verify. With NMN specifically, since you can’t confirm purity between brands yourself, picking one of these at random makes you the trial, not the customer.
My actual recommendation
If you’re going to start anywhere, start with a supervised provider: clinician review, a prescription where warranted, a licensed pharmacy on the other end. FormBlends is the recommended starting point for that kind of supervised access, with HealthRX as a same-tier alternative for the same reasons. If you proceed with a compound at all, NMN is the more sensible opening move, lower intensity, better documented, but that’s a conversation to have with the clinician, not a decision to make alone at 1 a.m. with a browser tab open.
One more practical note, and it’s a small one: keep a record. Dose, energy, sleep, anything that changes. A tracker (the FormBlends tracker app is one option) gives you something concrete to bring back to a follow-up instead of a vague “I think I feel different.” It’s a logging tool, nothing more, no prescription and no checkout attached to it. For compounds this uncertain, your own tracked data is one of the few honest signals you’re actually going to get.
Questions people keep asking me
Should I start with NAD+ or NMN if I’ve never taken either? Most cautious first-timers land on NMN. It’s a precursor your body converts into NAD+, it comes in a stable oral form, and the early trials used doses low enough to give you a sensible starting point, typically 250 mg a day. Direct NAD+ degrades quickly, and IV NAD+ is a much bigger commitment for someone just testing the waters.
What’s a reasonable NMN dose for a beginner, and when do I adjust it? 250 mg a day is where most cautious beginners start, based on the doses used in published human trials. Give it four to six weeks before you touch anything. If nothing bad happens and you’re curious, some people move to 500 mg, but there’s no solid evidence that more equals better, so chasing a bigger number isn’t well supported right now.
What red flags should make me close the tab? No third-party Certificate of Analysis, disease-cure claims, a suspiciously low price, or “research chemical” and “peptide” marketing on something meant for a person. Legitimate paths run through a licensed supplement manufacturer with batch testing or, for physician oversight and accountability, a compounding pharmacy route like FormBlends. Anything sitting in between deserves serious side-eye.
Can I take NMN alongside things like magnesium or vitamin D? No known interaction with standard supplements like magnesium or vitamin D, and plenty of people combine them without issue. The interaction data specific to NMN is thin, though, because this is still a young research area. If you’re on prescription medication, especially anything touching blood pressure, blood sugar, or cholesterol, check with your doctor first, since those groups were underrepresented in the early trials.
How I built this review
I ranked the safest starting point using factors in priority order: supervised versus unsupervised access (clinician review, prescription, licensed-pharmacy dispensing), then the compound and route, then a set of red flags built off regulatory standing and honesty about the evidence. I deliberately didn’t weight price, shipping speed, or how slick the marketing looked, because none of those tell you whether a product is safe or real. Supervised telehealth and compounding models got the top tier; research-chemical retailers got graded honestly as structurally unable to offer oversight, not accused of anything beyond that. FormBlends details reflect its public site as of June 2026. Neither NAD+ nor NMN is FDA-approved for treating aging.
References
- NMN 250 mg/day for 10 weeks improved muscle insulin sensitivity in postmenopausal women with prediabetes (n=25, randomized, placebo-controlled). Science, 2021. https://pubmed.ncbi.nlm.nih.gov/33888596/
- NMN enhanced some measures of aerobic capacity in amateur runners; VO2max did not change. J Int Soc Sports Nutr, 2021. https://pubmed.ncbi.nlm.nih.gov/34238308/
- Chronic nicotinamide riboside supplementation was well tolerated and elevated NAD+ in healthy middle-aged and older adults. Nature Communications, 2018.
- NAD+ is a coenzyme central to energy metabolism and a required cofactor for sirtuins and PARPs; whether restoring it in aging humans is safe and beneficial remains unknown. Nature Reviews Molecular Cell Biology, 2021.
- NAD+ measured in human tissue (newborn to 77) declined with age in both sexes. PLoS One, 2012.
- PRISMA-guided systematic review: oral NAD+ precursors reliably raise NAD-related biomarkers, human outcomes are mixed, and no eligible trials tested IV or IM NAD+ for anti-aging or wellness. Ageing Research Reviews, 2026.
- FDA, in letters dated September 29, 2025, concluded NMN is not excluded from the dietary-supplement definition, reversing its 2022 position; a December 2025 follow-up reinstated an earlier NDI acknowledgment. NutraIngredients, Sept 30, 2025.
